- Home
- EGAN vs GNFT Comparison
EGAN vs GNFT Comparison
Compare EGAN & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EGAN
- GNFT
- Stock Information
- Founded
- EGAN 1997
- GNFT 1999
- Country
- EGAN United States
- GNFT France
- Employees
- EGAN N/A
- GNFT N/A
- Industry
- EGAN Computer Software: Prepackaged Software
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EGAN Technology
- GNFT Health Care
- Exchange
- EGAN Nasdaq
- GNFT Nasdaq
- Market Cap
- EGAN 186.5M
- GNFT 172.2M
- IPO Year
- EGAN 1999
- GNFT 2019
- Fundamental
- Price
- EGAN $6.37
- GNFT $3.66
- Analyst Decision
- EGAN Buy
- GNFT Strong Buy
- Analyst Count
- EGAN 2
- GNFT 1
- Target Price
- EGAN $9.50
- GNFT $13.00
- AVG Volume (30 Days)
- EGAN 143.1K
- GNFT 6.9K
- Earning Date
- EGAN 02-06-2025
- GNFT 09-19-2024
- Dividend Yield
- EGAN N/A
- GNFT N/A
- EPS Growth
- EGAN 37.92
- GNFT N/A
- EPS
- EGAN 0.19
- GNFT 0.47
- Revenue
- EGAN $90,426,000.00
- GNFT $86,225,222.00
- Revenue This Year
- EGAN $1.52
- GNFT $145.20
- Revenue Next Year
- EGAN $10.05
- GNFT N/A
- P/E Ratio
- EGAN $34.20
- GNFT $7.56
- Revenue Growth
- EGAN N/A
- GNFT 175.45
- 52 Week Low
- EGAN $4.71
- GNFT $3.35
- 52 Week High
- EGAN $7.96
- GNFT $6.42
- Technical
- Relative Strength Index (RSI)
- EGAN 53.81
- GNFT 44.80
- Support Level
- EGAN $6.33
- GNFT $3.35
- Resistance Level
- EGAN $6.61
- GNFT $3.57
- Average True Range (ATR)
- EGAN 0.35
- GNFT 0.11
- MACD
- EGAN -0.03
- GNFT 0.02
- Stochastic Oscillator
- EGAN 41.10
- GNFT 56.36
About EGAN eGain Corporation
eGain Corp automates customer engagement with an innovative Software as a service (SaaS) platform, powered by deep digital, Artificial intelligence (AI), and knowledge capabilities. It operates in the United States, the United Kingdom, and India. The company derives maximum of its revenues from North America. It provides its products to industries such as financial services, telecommunications, retail, government, healthcare, and utilities.
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.